Share Price and Basic Stock Data
Last Updated: December 18, 2025, 9:20 pm
| PEG Ratio | 0.24 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ind-Swift Laboratories Ltd operates in the pharmaceuticals sector, focusing on manufacturing a variety of pharmaceutical products. As of March 2025, the company reported a total revenue of ₹562 Cr, a significant increase from ₹1,207 Cr in March 2023. This decline in revenue might raise eyebrows, but it is crucial to note that the reported figures show a substantial uptick in the last quarter of FY 2025, where sales jumped to ₹528.57 Cr. Despite the fluctuations, the company has demonstrated resilience, particularly in its recent quarter results. Moreover, the sales trajectory over the last few quarters reflects a somewhat inconsistent pattern, with the latest quarterly figures indicating a recovery phase. In particular, the operating profit margin (OPM) for the quarter ending June 2025 was reported at 2.36%, showcasing a decline from previous quarters but still indicative of operational activity.
Profitability and Efficiency Metrics
When analyzing profitability, Ind-Swift’s net profit was reported at ₹250 Cr for FY 2025, a marked improvement compared to the previous year’s ₹48 Cr. However, the operating profit for FY 2025 stood at a concerning negative ₹19 Cr, indicating challenges in maintaining operational efficiency. The company’s return on equity (ROE) is at 19.06%, which appears strong against many industry standards, suggesting that the company is effectively utilizing shareholders’ equity to generate profits. However, its return on capital employed (ROCE) of -0.90% in FY 2025 raises questions about how efficiently capital is being deployed. The cash conversion cycle (CCC) was recorded at 112 days, which indicates some inefficiencies in managing receivables and inventory, an area that could be improved to enhance cash flow.
Balance Sheet Strength and Financial Ratios
Ind-Swift’s balance sheet exhibits both strengths and vulnerabilities. The company reported total borrowings of merely ₹41 Cr, a significant reduction from ₹862 Cr in March 2023, indicating a strong effort towards deleveraging. This reduction enhances financial stability, as evidenced by a low debt-to-equity ratio of 0.03, suggesting a conservative approach to leveraging. However, the interest coverage ratio (ICR) is alarmingly low at 0.10x, implying that the company may struggle to meet its interest obligations, which can be a red flag for investors. Furthermore, the price-to-book value (P/BV) ratio stands at 0.49x, indicating that the stock is trading at a discount relative to its book value, which might attract value investors seeking undervalued assets. The reserves have also seen a robust increase, standing at ₹1,104 Cr, which provides a cushion for future growth and operational needs.
Shareholding Pattern and Investor Confidence
Ind-Swift’s shareholding structure reveals a diverse composition that might influence investor confidence. As of March 2025, promoters hold 40.94% of the shares, a notable decrease from 42.01% in previous quarters, which could signal a shift in management’s commitment or strategy. Foreign institutional investors (FIIs) have significantly increased their stake to 14.80% from a mere 0.04% in December 2022, reflecting growing confidence from international investors. On the other hand, the presence of domestic institutional investors (DIIs) has dwindled to 0.68%. This decline may raise concerns about local institutional support and could affect stock liquidity. The public shareholding has also decreased to 45.02%, potentially indicating a consolidation trend among larger shareholders. Such dynamics can impact the stock’s volatility and perceived stability in the market.
Outlook, Risks, and Final Insight
The outlook for Ind-Swift Laboratories appears mixed, with notable strengths offset by significant risks. On one hand, the company’s reduced debt levels and increased reserves suggest a more secure financial footing, which could pave the way for potential growth opportunities. However, the volatility in revenue and profitability metrics raises concerns about operational efficiency and market competitiveness. Investors should be cautious of the low interest coverage ratio, which signals potential liquidity issues. Furthermore, the fluctuation in shareholding patterns, particularly the drop in promoter holdings, might be perceived as a lack of confidence from the management side. As such, retail investors might consider monitoring the company’s operational strategies closely, particularly how it navigates its profitability challenges and leverages its financial strengths to foster growth in the coming quarters.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 116 | 235/84.3 | 32.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,239 Cr. | 389 | 479/192 | 87.8 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.8 Cr. | 45.5 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.2 Cr. | 32.9 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,006.85 Cr | 1,144.50 | 52.26 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 280.17 | 310.21 | 312.69 | 304.25 | 310.34 | 289.71 | 287.51 | 528.57 | 33.17 | 11.96 | 124.66 | 138.24 | 152.73 |
| Expenses | 227.16 | 251.45 | 258.93 | 240.58 | 250.05 | 224.02 | 235.82 | 437.36 | 42.91 | 23.76 | 131.31 | 147.44 | 149.13 |
| Operating Profit | 53.01 | 58.76 | 53.76 | 63.67 | 60.29 | 65.69 | 51.69 | 91.21 | -9.74 | -11.80 | -6.65 | -9.20 | 3.60 |
| OPM % | 18.92% | 18.94% | 17.19% | 20.93% | 19.43% | 22.67% | 17.98% | 17.26% | -29.36% | -98.66% | -5.33% | -6.66% | 2.36% |
| Other Income | 7.39 | 7.54 | 8.36 | -16.44 | 5.61 | 7.40 | 7.11 | 458.23 | 11.14 | 13.01 | 15.91 | 220.34 | 14.58 |
| Interest | 23.98 | 23.98 | 22.38 | 21.82 | 20.38 | 21.14 | 21.05 | 2.96 | 0.17 | 0.41 | 10.03 | -26.76 | 1.15 |
| Depreciation | 16.28 | 16.41 | 15.39 | 9.29 | 13.89 | 13.19 | 13.56 | 19.55 | 0.25 | 0.22 | 5.81 | 7.44 | 6.68 |
| Profit before tax | 20.14 | 25.91 | 24.35 | 16.12 | 31.63 | 38.76 | 24.19 | 526.93 | 0.98 | 0.58 | -6.58 | 230.46 | 10.35 |
| Tax % | 1.09% | 2.16% | -13.43% | 255.40% | 45.02% | 17.88% | 19.31% | 6.29% | -3.06% | 31.03% | -16.41% | 3.55% | 16.52% |
| Net Profit | 19.88 | 25.34 | 27.50 | -25.12 | 17.24 | 31.66 | 19.42 | 493.68 | 0.94 | 0.41 | -5.49 | 222.27 | 8.77 |
| EPS in Rs | 3.36 | 4.29 | 4.65 | -4.25 | 2.92 | 5.36 | 3.29 | 83.55 | 0.16 | 0.07 | -0.93 | 36.67 | 1.45 |
Last Updated: August 20, 2025, 9:05 am
Below is a detailed analysis of the quarterly data for Ind-Swift Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 152.73 Cr.. The value appears strong and on an upward trend. It has increased from 138.24 Cr. (Mar 2025) to 152.73 Cr., marking an increase of 14.49 Cr..
- For Expenses, as of Jun 2025, the value is 149.13 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 147.44 Cr. (Mar 2025) to 149.13 Cr., marking an increase of 1.69 Cr..
- For Operating Profit, as of Jun 2025, the value is 3.60 Cr.. The value appears strong and on an upward trend. It has increased from -9.20 Cr. (Mar 2025) to 3.60 Cr., marking an increase of 12.80 Cr..
- For OPM %, as of Jun 2025, the value is 2.36%. The value appears strong and on an upward trend. It has increased from -6.66% (Mar 2025) to 2.36%, marking an increase of 9.02%.
- For Other Income, as of Jun 2025, the value is 14.58 Cr.. The value appears to be declining and may need further review. It has decreased from 220.34 Cr. (Mar 2025) to 14.58 Cr., marking a decrease of 205.76 Cr..
- For Interest, as of Jun 2025, the value is 1.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from -26.76 Cr. (Mar 2025) to 1.15 Cr., marking an increase of 27.91 Cr..
- For Depreciation, as of Jun 2025, the value is 6.68 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.44 Cr. (Mar 2025) to 6.68 Cr., marking a decrease of 0.76 Cr..
- For Profit before tax, as of Jun 2025, the value is 10.35 Cr.. The value appears to be declining and may need further review. It has decreased from 230.46 Cr. (Mar 2025) to 10.35 Cr., marking a decrease of 220.11 Cr..
- For Tax %, as of Jun 2025, the value is 16.52%. The value appears to be increasing, which may not be favorable. It has increased from 3.55% (Mar 2025) to 16.52%, marking an increase of 12.97%.
- For Net Profit, as of Jun 2025, the value is 8.77 Cr.. The value appears to be declining and may need further review. It has decreased from 222.27 Cr. (Mar 2025) to 8.77 Cr., marking a decrease of 213.50 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.45. The value appears to be declining and may need further review. It has decreased from 36.67 (Mar 2025) to 1.45, marking a decrease of 35.22.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:11 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 965 | 660 | 653 | 716 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,709 | 562 | 568 |
| Expenses | 906 | 571 | 546 | 610 | 631 | 630 | 635 | 709 | 837 | 978 | 1,403 | 581 | 579 |
| Operating Profit | 59 | 89 | 107 | 106 | 134 | 126 | 144 | 183 | 202 | 229 | 306 | -19 | -11 |
| OPM % | 6% | 13% | 16% | 15% | 18% | 17% | 19% | 21% | 19% | 19% | 18% | -3% | -2% |
| Other Income | -19 | -31 | 1 | 15 | 16 | 120 | 33 | 23 | 37 | 7 | 476 | 305 | 269 |
| Interest | 117 | 117 | 106 | 88 | 28 | 92 | 107 | 100 | 96 | 92 | 104 | 3 | -14 |
| Depreciation | 66 | 84 | 85 | 88 | 87 | 104 | 90 | 87 | 131 | 57 | 80 | 24 | 27 |
| Profit before tax | -142 | -143 | -83 | -55 | 36 | 50 | -20 | 18 | 13 | 87 | 598 | 258 | 245 |
| Tax % | -14% | -17% | -29% | -29% | 39% | 42% | 7% | 117% | 117% | 45% | 10% | 3% | |
| Net Profit | -122 | -119 | -59 | -39 | 22 | 29 | -21 | -3 | -2 | 48 | 539 | 250 | 234 |
| EPS in Rs | -29.79 | -29.14 | -14.33 | -8.75 | 4.85 | 6.09 | -3.59 | -0.53 | -0.36 | 8.06 | 91.18 | 41.32 | 38.17 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 2.46% | 50.42% | 33.90% | 156.41% | 31.82% | -172.41% | 85.71% | 33.33% | 2500.00% | 1022.92% | -53.62% |
| Change in YoY Net Profit Growth (%) | 0.00% | 47.96% | -16.52% | 122.51% | -124.59% | -204.23% | 258.13% | -52.38% | 2466.67% | -1477.08% | -1076.53% |
Ind-Swift Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -6% |
| 3 Years: | -19% |
| TTM: | -62% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 30% |
| 3 Years: | 205% |
| TTM: | -88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 24% |
| 3 Years: | 20% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 6% |
| 3 Years: | 10% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 7:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:51 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 41 | 42 | 42 | 45 | 46 | 48 | 60 | 60 | 60 | 60 | 67 | 69 | 82 |
| Reserves | 684 | 553 | 476 | 486 | 507 | 540 | 581 | 544 | 541 | 622 | 745 | 1,104 | 1,226 |
| Borrowings | 1,355 | 1,413 | 1,457 | 1,242 | 1,083 | 1,148 | 1,031 | 1,005 | 953 | 862 | 217 | 41 | 22 |
| Other Liabilities | 258 | 236 | 240 | 364 | 387 | 188 | 198 | 210 | 247 | 280 | 432 | 224 | 215 |
| Total Liabilities | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 | 1,544 |
| Fixed Assets | 1,174 | 1,117 | 1,099 | 1,042 | 934 | 914 | 843 | 753 | 630 | 587 | 192 | 273 | 285 |
| CWIP | 78 | 113 | 78 | 70 | 69 | 20 | 11 | 19 | 10 | 8 | 51 | 0 | 0 |
| Investments | 17 | 18 | 18 | 18 | 18 | 19 | 17 | 36 | 29 | 30 | 112 | 213 | 312 |
| Other Assets | 1,070 | 997 | 1,020 | 1,007 | 1,002 | 972 | 998 | 1,011 | 1,131 | 1,199 | 1,106 | 952 | 947 |
| Total Assets | 2,339 | 2,244 | 2,215 | 2,138 | 2,023 | 1,924 | 1,870 | 1,818 | 1,801 | 1,824 | 1,460 | 1,438 | 1,544 |
Below is a detailed analysis of the balance sheet data for Ind-Swift Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 82.00 Cr.. The value appears strong and on an upward trend. It has increased from 69.00 Cr. (Mar 2025) to 82.00 Cr., marking an increase of 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,226.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,104.00 Cr. (Mar 2025) to 1,226.00 Cr., marking an increase of 122.00 Cr..
- For Borrowings, as of Sep 2025, the value is 22.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 41.00 Cr. (Mar 2025) to 22.00 Cr., marking a decrease of 19.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 215.00 Cr.. The value appears to be improving (decreasing). It has decreased from 224.00 Cr. (Mar 2025) to 215.00 Cr., marking a decrease of 9.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,544.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,438.00 Cr. (Mar 2025) to 1,544.00 Cr., marking an increase of 106.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 285.00 Cr.. The value appears strong and on an upward trend. It has increased from 273.00 Cr. (Mar 2025) to 285.00 Cr., marking an increase of 12.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 312.00 Cr.. The value appears strong and on an upward trend. It has increased from 213.00 Cr. (Mar 2025) to 312.00 Cr., marking an increase of 99.00 Cr..
- For Other Assets, as of Sep 2025, the value is 947.00 Cr.. The value appears to be declining and may need further review. It has decreased from 952.00 Cr. (Mar 2025) to 947.00 Cr., marking a decrease of 5.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,544.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,438.00 Cr. (Mar 2025) to 1,544.00 Cr., marking an increase of 106.00 Cr..
Notably, the Reserves (1,226.00 Cr.) exceed the Borrowings (22.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 58.00 | 88.00 | 106.00 | 105.00 | 133.00 | 125.00 | 143.00 | 182.00 | -751.00 | -633.00 | 89.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 168 | 215 | 208 | 182 | 194 | 169 | 186 | 177 | 160 | 153 | 48 | 107 |
| Inventory Days | 182 | 312 | 368 | 305 | 291 | 284 | 315 | 301 | 288 | 242 | 6 | 145 |
| Days Payable | 103 | 120 | 137 | 91 | 118 | 114 | 124 | 111 | 118 | 113 | 52 | 140 |
| Cash Conversion Cycle | 247 | 407 | 439 | 396 | 367 | 339 | 377 | 367 | 330 | 282 | 2 | 112 |
| Working Capital Days | 129 | 141 | -26 | -97 | -49 | 217 | 248 | 253 | 253 | 234 | 2 | 141 |
| ROCE % | 0% | 1% | 2% | 2% | 4% | 4% | 5% | 7% | 7% | 13% | 20% | 3% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 37.25 | 71.24 | 8.10 | -0.36 | -0.53 |
| Diluted EPS (Rs.) | 35.21 | 71.24 | 8.10 | -0.36 | -0.53 |
| Cash EPS (Rs.) | 40.00 | 80.35 | 17.59 | 21.55 | 14.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 170.88 | 157.64 | 83.36 | 67.61 | 65.66 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 170.88 | 157.64 | 114.02 | 100.47 | 100.90 |
| Revenue From Operations / Share (Rs.) | 81.71 | 216.78 | 201.87 | 173.68 | 149.04 |
| PBDIT / Share (Rs.) | 9.02 | 50.70 | 43.92 | 39.98 | 34.36 |
| PBIT / Share (Rs.) | 5.46 | 41.68 | 34.33 | 18.07 | 19.77 |
| PBT / Share (Rs.) | 37.50 | 98.46 | 14.47 | 2.10 | 3.01 |
| Net Profit / Share (Rs.) | 36.44 | 71.33 | 8.00 | -0.35 | -0.52 |
| NP After MI And SOA / Share (Rs.) | 36.44 | 71.24 | 7.96 | -0.35 | -0.52 |
| PBDIT Margin (%) | 11.03 | 23.38 | 21.75 | 23.01 | 23.05 |
| PBIT Margin (%) | 6.67 | 19.22 | 17.00 | 10.40 | 13.26 |
| PBT Margin (%) | 45.89 | 45.41 | 7.16 | 1.20 | 2.02 |
| Net Profit Margin (%) | 44.60 | 32.90 | 3.96 | -0.20 | -0.35 |
| NP After MI And SOA Margin (%) | 44.59 | 32.86 | 3.94 | -0.20 | -0.35 |
| Return on Networth / Equity (%) | 21.32 | 45.19 | 9.54 | -0.53 | -0.80 |
| Return on Capital Employeed (%) | 3.08 | 26.09 | 14.13 | 7.36 | 7.86 |
| Return On Assets (%) | 17.41 | 36.13 | 2.60 | -0.11 | -0.17 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 1.51 | 2.10 | 2.25 |
| Total Debt / Equity (X) | 0.02 | 0.01 | 1.73 | 2.35 | 2.56 |
| Asset Turnover Ratio (%) | 0.43 | 0.85 | 0.66 | 0.54 | 0.46 |
| Current Ratio (X) | 3.92 | 2.99 | 3.14 | 3.22 | 3.00 |
| Quick Ratio (X) | 3.41 | 2.94 | 1.96 | 1.94 | 1.81 |
| Inventory Turnover Ratio (X) | 9.01 | 5.70 | 1.52 | 1.33 | 1.23 |
| Interest Coverage Ratio (X) | 21.24 | 5.86 | 2.85 | 2.50 | 2.05 |
| Interest Coverage Ratio (Post Tax) (X) | 10.36 | 1.68 | 1.81 | 0.97 | 0.96 |
| Enterprise Value (Cr.) | 189.85 | 165.50 | 1173.71 | 1328.01 | 1424.06 |
| EV / Net Operating Revenue (X) | 0.33 | 0.12 | 0.97 | 1.28 | 1.60 |
| EV / EBITDA (X) | 3.06 | 0.55 | 4.47 | 5.55 | 6.93 |
| MarketCap / Net Operating Revenue (X) | 1.03 | 0.45 | 0.27 | 0.38 | 0.48 |
| Price / BV (X) | 0.49 | 0.62 | 0.66 | 0.98 | 1.10 |
| Price / Net Operating Revenue (X) | 1.03 | 0.45 | 0.27 | 0.38 | 0.48 |
| EarningsYield | 0.43 | 0.72 | 0.14 | -0.01 | -0.01 |
After reviewing the key financial ratios for Ind-Swift Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 37.25. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 37.25, marking a decrease of 33.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 35.21. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 35.21, marking a decrease of 36.03.
- For Cash EPS (Rs.), as of Mar 25, the value is 40.00. This value is within the healthy range. It has decreased from 80.35 (Mar 24) to 40.00, marking a decrease of 40.35.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.88. It has increased from 157.64 (Mar 24) to 170.88, marking an increase of 13.24.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 170.88. It has increased from 157.64 (Mar 24) to 170.88, marking an increase of 13.24.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 81.71. It has decreased from 216.78 (Mar 24) to 81.71, marking a decrease of 135.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 9.02. This value is within the healthy range. It has decreased from 50.70 (Mar 24) to 9.02, marking a decrease of 41.68.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.46. This value is within the healthy range. It has decreased from 41.68 (Mar 24) to 5.46, marking a decrease of 36.22.
- For PBT / Share (Rs.), as of Mar 25, the value is 37.50. This value is within the healthy range. It has decreased from 98.46 (Mar 24) to 37.50, marking a decrease of 60.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 36.44. This value is within the healthy range. It has decreased from 71.33 (Mar 24) to 36.44, marking a decrease of 34.89.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 36.44. This value is within the healthy range. It has decreased from 71.24 (Mar 24) to 36.44, marking a decrease of 34.80.
- For PBDIT Margin (%), as of Mar 25, the value is 11.03. This value is within the healthy range. It has decreased from 23.38 (Mar 24) to 11.03, marking a decrease of 12.35.
- For PBIT Margin (%), as of Mar 25, the value is 6.67. This value is below the healthy minimum of 10. It has decreased from 19.22 (Mar 24) to 6.67, marking a decrease of 12.55.
- For PBT Margin (%), as of Mar 25, the value is 45.89. This value is within the healthy range. It has increased from 45.41 (Mar 24) to 45.89, marking an increase of 0.48.
- For Net Profit Margin (%), as of Mar 25, the value is 44.60. This value exceeds the healthy maximum of 10. It has increased from 32.90 (Mar 24) to 44.60, marking an increase of 11.70.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 44.59. This value exceeds the healthy maximum of 20. It has increased from 32.86 (Mar 24) to 44.59, marking an increase of 11.73.
- For Return on Networth / Equity (%), as of Mar 25, the value is 21.32. This value is within the healthy range. It has decreased from 45.19 (Mar 24) to 21.32, marking a decrease of 23.87.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.08. This value is below the healthy minimum of 10. It has decreased from 26.09 (Mar 24) to 3.08, marking a decrease of 23.01.
- For Return On Assets (%), as of Mar 25, the value is 17.41. This value is within the healthy range. It has decreased from 36.13 (Mar 24) to 17.41, marking a decrease of 18.72.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.43. It has decreased from 0.85 (Mar 24) to 0.43, marking a decrease of 0.42.
- For Current Ratio (X), as of Mar 25, the value is 3.92. This value exceeds the healthy maximum of 3. It has increased from 2.99 (Mar 24) to 3.92, marking an increase of 0.93.
- For Quick Ratio (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 2. It has increased from 2.94 (Mar 24) to 3.41, marking an increase of 0.47.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.01. This value exceeds the healthy maximum of 8. It has increased from 5.70 (Mar 24) to 9.01, marking an increase of 3.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 21.24. This value is within the healthy range. It has increased from 5.86 (Mar 24) to 21.24, marking an increase of 15.38.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 10.36. This value is within the healthy range. It has increased from 1.68 (Mar 24) to 10.36, marking an increase of 8.68.
- For Enterprise Value (Cr.), as of Mar 25, the value is 189.85. It has increased from 165.50 (Mar 24) to 189.85, marking an increase of 24.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 1. It has increased from 0.12 (Mar 24) to 0.33, marking an increase of 0.21.
- For EV / EBITDA (X), as of Mar 25, the value is 3.06. This value is below the healthy minimum of 5. It has increased from 0.55 (Mar 24) to 3.06, marking an increase of 2.51.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 1.03, marking an increase of 0.58.
- For Price / BV (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.62 (Mar 24) to 0.49, marking a decrease of 0.13.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.03. This value is within the healthy range. It has increased from 0.45 (Mar 24) to 1.03, marking an increase of 0.58.
- For EarningsYield, as of Mar 25, the value is 0.43. This value is below the healthy minimum of 5. It has decreased from 0.72 (Mar 24) to 0.43, marking a decrease of 0.29.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ind-Swift Laboratories Ltd:
- Net Profit Margin: 44.6%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.08% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 21.32% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 10.36
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 25.9 (Industry average Stock P/E: 52.26)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 44.6%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | SCO 850, Shivalik Enclave, Chandigarh Chandigarh 160101 | investor@indswiftlabs.com http://www.indswiftlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Navrattan Munjal | Chairman & Managing Director |
| Mr. Himanshu Jain | Joint Managing Director |
| Mr. Rishav Mehta | Executive Director |
| Mr. Sahil Munjal | Executive Director |
| Mr. Rajinder Kumar Gupta | Independent Director |
| Mr. Prabhat Khurana | Independent Director |
| Mr. Subodh Gupta | Independent Director |
| Ms. Neerja Chathley | Independent Woman Director |
FAQ
What is the intrinsic value of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd's intrinsic value (as of 18 December 2025) is 6.09 which is 93.52% lower the current market price of 94.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 768 Cr. market cap, FY2025-2026 high/low of 124/67.2, reserves of ₹1,226 Cr, and liabilities of 1,544 Cr.
What is the Market Cap of Ind-Swift Laboratories Ltd?
The Market Cap of Ind-Swift Laboratories Ltd is 768 Cr..
What is the current Stock Price of Ind-Swift Laboratories Ltd as on 18 December 2025?
The current stock price of Ind-Swift Laboratories Ltd as on 18 December 2025 is 94.0.
What is the High / Low of Ind-Swift Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ind-Swift Laboratories Ltd stocks is 124/67.2.
What is the Stock P/E of Ind-Swift Laboratories Ltd?
The Stock P/E of Ind-Swift Laboratories Ltd is 25.9.
What is the Book Value of Ind-Swift Laboratories Ltd?
The Book Value of Ind-Swift Laboratories Ltd is 160.
What is the Dividend Yield of Ind-Swift Laboratories Ltd?
The Dividend Yield of Ind-Swift Laboratories Ltd is 0.00 %.
What is the ROCE of Ind-Swift Laboratories Ltd?
The ROCE of Ind-Swift Laboratories Ltd is 0.78 %.
What is the ROE of Ind-Swift Laboratories Ltd?
The ROE of Ind-Swift Laboratories Ltd is 0.18 %.
What is the Face Value of Ind-Swift Laboratories Ltd?
The Face Value of Ind-Swift Laboratories Ltd is 10.0.